Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12786637 | 0.87 | MEN1 (0.35) | HPGDMEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL13586125 | 0.86 | ALOX5AP (0.35) | HPGDMEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL12823695 | 0.86 | ALOX5AP (0.35) | HPGDMEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL8971424 | 0.85 | HPGD (0.41) | HPGDMEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL12717614 | 0.85 | ALOX5AP (0.33) | HPGDMEN1KMT2A | |
| SCHEMBL12822555 | 0.84 | ALOX5AP (0.39) | OXTRAVPR1A | |
| SCHEMBL12823979 | 0.84 | ALOX5AP (0.39) | OXTRAVPR1A | |
| SCHEMBL12822910 | 0.83 | HPGD (0.39) | HPGDMEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL12823327 | 0.83 | HPGD (0.39) | HPGDMEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL12823346 | 0.82 | PDE4A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | HPGD 4487/4885MEN1 3734/4885RAB9A 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.